CD8A and glioblastoma: Because in GBM NY-ESO-1 expression is silenced by CpG hypermethylation, decitabine reactivates NY-ESO-1 expression by reversing DNA hypermethylation, enhancing CD8+ T cell response, and leading to robust antitumor activity.